Trials / Active Not Recruiting
Active Not RecruitingNCT05064358
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 2, Randomized, Parallel, Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-agent Belantamab Mafodotin (GSK2857916) in Participants With Relapsed or Refractory Multiple Myeloma (DREAMM-14)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 177 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be achieved by modifying the belantamab mafodotin dose, schedule, or both.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Belantamab mafodotin | Belantamab mafodotin will be administered. |
Timeline
- Start date
- 2022-03-03
- Primary completion
- 2024-08-19
- Completion
- 2026-01-30
- First posted
- 2021-10-01
- Last updated
- 2025-10-07
- Results posted
- 2025-10-07
Locations
88 sites across 19 countries: United States, Argentina, Australia, Brazil, Canada, France, Germany, Greece, India, Ireland, Italy, Mexico, Poland, South Korea, Spain, Switzerland, Taiwan, Thailand, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05064358. Inclusion in this directory is not an endorsement.